Key Drivers
- Strong liquidity
- High cash burn
- Low leverage
AIAI Summary
Erasca's upsized financing, patent and rights moves convert it from a binary early‑stage gamble into a funded, multi‑catalyst clinical‑stage platform, but the stock's premium and dilution mean near‑term value now pivots entirely on positive ERAS‑0015 Phase‑1 readouts and partnership execution—monitor H1 2026 data, cash burn pacing, and deal milestones as the decisive re‑rating or dilution triggers.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •High cash burn
- •Low leverage
Strong balance-sheet with ample liquidity and low leverage but zero revenue, large R&D-driven operating losses and cash burn, and a market valuation that far exceeds fundamentals.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Near-term resistance
- •Elevated volatility
Over the last month ERAS climbed ~16% from $12.54 to $14.60, trading with higher lows (support ~$12.50) and near-term resistance at $15.7–$15.8, with elevated ~25% volatility and a 7% pullback from the $15.76 high suggesting consolidation rather than a reversal.
Intraperiod high $15.76 and ~25% price range indicate heightened short-term volatility
Sentiment & News
Key News Insights:
- •Patent extension
- •ERAS‑0015 responses
- •Global rights deal
Erasca's February–March 2026 catalysts — a U.S. patent for pan‑KRAS ERAS‑4001, promising early ERAS‑0015 activity with planned H1 Phase 1 data, China rights and a Tango collaboration — drove heightened analyst focus and a stock rally ahead of key readouts.
These developments should lift investor sentiment and valuation near-term by de‑risking IP and broadening development pathways, while ultimate upside depends on forthcoming ERAS‑0015 clinical readouts
Similar Companies in Healthcare
Other companies in the same sector with AI ratings